Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IIIA Non-Small Cell Lung Cancer: early-phase trial registry
A small indexed set (11 trials) with no open enrollment listed right now.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · none currently recruiting · #1,577 of 28,707 conditions by registered trial count
Stage IIIA Non-Small Cell Lung Cancer: 11 US clinical trials tracked, none currently recruiting.
Stage IIIA Non-Small Cell Lung Cancer is the subject of 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is University of Southern California, running 2 of these trials.
Enrollment posture brief
Registry condition stage-iiia-non-small-cell-lung-cancer
OPEN 0 | RECR 0% | LATE 0 | EARLY 10 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Stage IIIA Non-Small Cell Lung Cancer has no open enrollment in this registry pull (11 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IIIA Non-Small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IIIA Non-Small Cell Lung Cancer is recruiting below its size-band peers.
0 of 11 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IIIA Non-Small Cell Lung Cancer research.
University of Southern California accounts for 2 of 11 trials (18.2%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IIIA Non-Small Cell Lung Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 27 among the 11 trials that report a genuine target (sentinel values excluded). 11 of those (100%) plan for fewer than 100 participants.
-
Stage IIIA Non-Small Cell Lung Cancer research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
11 total, page 1 of 1
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
NCT02495896
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Alliance Foundation Trials
NCT04062708
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Jonsson Comprehensive Cancer Center
NCT01345851
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
University of California, San Francisco
NCT03433469
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00387465
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
University of Southern California
NCT03049618
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
NCT02621398
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00778167
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
Roswell Park Cancer Institute
NCT01781741
Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
Shionogi
NCT00078390
18F-FSPG PET/CT for Cancer Patients on Therapy
Andrei Iagaru
NCT02599194
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IIIA Non-Small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IIIA Non-Small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IIIA Non-Small Cell Lung Cancer page
11 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Stage IIIA Non-Small Cell Lung Cancer trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- University of Southern California sponsors the most Stage IIIA Non-Small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See University of Southern California's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIIA Non-Small Cell Lung Cancer condition card totals 11 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.